Anzeige
Mehr »
Login
Donnerstag, 12.09.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Lachender Gewinner? Warum diese Rohstoffaktie alles überstrahlen könnte!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DR6E | ISIN: CA60255C8850 | Ticker-Symbol: MMQ
Tradegate
11.09.24
18:50 Uhr
5,350 Euro
+0,050
+0,94 %
Branche
Rohstoffe
Aktienmarkt
Sonstige
1-Jahres-Chart
MIND MEDICINE MINDMED INC Chart 1 Jahr
5-Tage-Chart
MIND MEDICINE MINDMED INC 5-Tage-Chart
RealtimeGeldBriefZeit
5,3255,53511.09.
5,3755,49011.09.

Aktuelle News zur MIND MEDICINE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoMind Medicine Inc.: MindMed Announces New Employee Inducement Grants280Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced...
► Artikel lesen
04.09.Mind Medicine Inc.: MindMed to Participate in September Investor Conferences165Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced...
► Artikel lesen
21.08.Mind Medicine CEO Robert Barrow buys $6,215 in shares14
13.08.Mind Medicine (MindMed) Inc reports results for the quarter ended in June - Earnings Summary6
13.08.Mind Medicine Inc. - 10-Q, Quarterly Report5
13.08.Mind Medicine Inc.: MindMed Reports Second Quarter 2024 Financial Results and Business Updates351--Completed End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA); on track to initiate Phase 3 clinical program for MM120 orally disintegrating tablet (ODT) in Generalized...
► Artikel lesen
13.08.MindMed Reports Second Quarter 2024 Financial Results and Business Updates87NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain...
► Artikel lesen
12.08.Psychedelics Company MindMed Prices Public Offering Aiming To Raise $75M8
12.08.Mind Medicine Q2 2024 Earnings Preview4
12.08.Mind Medicine Inc. - 8-K, Current Report3
09.08.MindMed announces mega-million public offering9
09.08.Mind Medicine prices $75M securities offering2
09.08.Mind Medicine (MindMed) Inc. Announces Pricing of Public Offering306Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced...
► Artikel lesen
09.08.Mind Medicine stock dips on proposed securities offering5
09.08.Mind Medicine (MindMed) Inc. Announces Proposed Public Offering226Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced...
► Artikel lesen
06.08.Mind Medicine Inc.: MindMed to Present at Canaccord Genuity's 44th Annual Growth Conference242Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced...
► Artikel lesen
06.08.Mind Medicine Inc.: MindMed to Host Conference Call and Webcast to Discuss Second Quarter 2024 Financial Results and Provide Business Update188Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced...
► Artikel lesen
29.07.Mind Medicine Inc.: MindMed Appoints Stephanie Fagan as Chief Corporate Affairs Officer298Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced...
► Artikel lesen
17.07.Mind Medicine Inc.: MindMed Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet (ODT)460- New patent covers MM120 ODT formulation and extends patent term to 2041- - Claims include pharmaceutical formulation, methods of manufacturing and methods of treatment for MM120 ODT- Mind...
► Artikel lesen
28.06.Mind Medicine Inc. - 8-K, Current Report10
Seite:  Weiter >>
60 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,5